Literature DB >> 28560446

Prediction of marker genes associated with hypertension by bioinformatics analyses.

Yuan Gao1, Guo-Xian Qi1, Zhi-Mei Jia1, Ying-Xian Sun1.   

Abstract

This study aimed to explore the underlying marker genes associated with hypertension by bioinformatics analyses. A gene expression profile (GSE54015) was downloaded. The differentially expressed genes (DEGs) between the normotensive female (NF) and hypertensive female (HF), and between the normotensive male (NM) and hypertensive male (HM) groups were analyzed. Gene Ontology (GO) and pathway enrichment analyses were performed, followed by protein-protein interaction (PPI) network construction. The transcription factors (TFs), and the common DEGs between the HF and HM groups were then analyzed. In total, 411 DEGs were identified between the HF and NF groups, and 418 DEGs were identified between the HM and NM groups. The upregulated DEGs in the HF and HM groups were enriched in 9 GO terms, including oxidation reduction, such as cytochrome P450, family 4, subfamily b, polypeptide 1 (Cyp4b1) and cytochrome P450, family 4, subfamily a, polypeptide 31 Cyp4a31). The downregulated DEGs were mainly enriched in GO terms related to hormone metabolic processes. In the PPI network, cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1) had the highest degree in all 3 analysis methods in the HF group. Additionally, 4 TFs were indentified from the 2 groups of data, including sterol regulatory element binding transcription factor 1 (Srebf1), estrogen receptor 1 (Esr1), retinoid X receptor gamma (Rxrg) and peroxisome proliferator-activated receptor gamma (Pparg). The intersection genes were mainly enriched in GO terms related to the extracellular region. On the whole, our data indicate that the DEGs, Cyp4b1, Cyp4a31 and Loxl2, and the TFs, Esr1, Pparg and Rxrg, are associated with the progression of hypertension, and may thus serve as potential therapeutic targets in this disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28560446      PMCID: PMC5466388          DOI: 10.3892/ijmm.2017.3000

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


Introduction

Hypertension, also known as arterial hypertension, is a chronic medical condition in which the blood pressure in the arteries is elevated (1). Hypertension is classified as either primary or secondary hypertension, and primary hypertension accounts for approximately 90–95% of cases (2). In primary hypertension, the cause of the hypertensioin is not clearly defined, whereas in secondary hyptertension, the cause of the high blood pressure is clearly determined. Hypertension can lead to cardiac hypertrophy, aortic dissection and heart failure, due to structural changes in blood vessel walls and in the heart muscle, which has become a major burden to healthcare systems (3). Thus, hypertension is the leading risk factor for cardiovascular disease (4). According to a report of the World Health Organization in 2011, cardiovascular diseases are the leading cause of morbidity and mortality worldwide (5). As a multifactorial disease, hypertension results from a complex interaction of environmental factors and genetic factors (6). Numerous common genetic variants, as well as some rare genetic variants have been identified to affact blood pressure (7,8). For instance, bone morphogenetic protein receptor type 2, which belongs to the transforming growth factor (TGF)-β superfamily of receptors, has been found to be mutated in the majority of cases of hypertension (9). Interleukin (IL)-17 has also been thought to be involved in hypertension due to its role in increasing the production of some other immune system chemical signals, such as IL-1, IL-6 and tumor necrosis factor (TNF)-α (10). Additionally, Austin et al (11) suggested that mutations in caveolin-1 are associated with pulmonary arterial hypertension. Despite advances in understanding the etiology of hypertension, the genetic basis responsible for this disease remains poorly elucidated. Presently, there are many species of animals used as models of hypertension. In our study, the microarray dataset, GSE54015, which contained data from Schlager BPH/2J and BPN/3J mouse models was downloaded for analysis. of note, Puig et al (12) also used the same mouse models to identify potential pharmacological targets of hypertension. In this study, we identified the differentially expressed genes (DEGs) between normotensive mice and hypertensive mice of both genders. Additionally, we performed functional enrichment analyses and protein-protein interaction (PPI) networks analysis to study and identify the pathways and DEGs associated with hypertension. Furthermore, transcription factors (TFs) and DEGs in both hypertensive female (HF) and male (HM) groups were analyzed. The results of this study may aid in the diagnosis and treatment of hypertension.

Data collection methods

Affymetrix microarray data

The microarray data of GSE54015 were downloaded, which was deposited in the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) database by Chiu et al (2). The platform is [MoGene-1_1-st] Affymetrix Mouse Gene 1.1 ST array [transcript (gene) version]. In the study by Chiu et al (2), 12- to 13-week-old Schlager hypertensive male and hypertensive female BPH/2J, and normotensive male and normotensive female BPN/3J mice (n=6/group) were used, and their kidney tissues were collected for the microarrays. In the present study, 4 types of mouse samples were used for analysis: normotensive female (NF) BPN/3J, hypertensive female (HF) BPH/2J, normotensive male (NM) BPN/3J and hypertensive male (HM) BPH/2J mice.

Data pre-processing and analysis of DEGs

The CEL raw data were downloaded and preprocessed using oligo (13) in R of Bioconductor (http://www.bioconductor.org/packages/release/bioc/html/) with the method of robust multiarray average (RMA) (14). The preprocessing processes included background correction, quartile data normalization and probe summarization. The paired t-test based on the limma package (15) (no. 1406, Ritchie, 2015) in Bioconductor was used to identify the DEGs between the HF and NF groups, and between the HM and NM groups. The false discovery rate (FDR) was calculated to adjust the P-value with the Benjamini-Hochberg method (16). Only genes with |log2FC| ≥0.58 and an adjusted P-value <0.05 were regarded as DEGs.

Gene ontology (GO) and pathway enrichment analyses

The GO (http://www.geneontology.org) project is used to provide consistent descriptors for gene products in different databases, and to standardize classifications for sequences (17). Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.ad.jp/kegg/) is a knowledge base used to analyze gene functions, and to link genomic information with higher order functional information (18). In this study, the obtained DEGs were performed GO and KEGG pathway enrichment analyses to obtain the biological process (BP), molecular function (MF), cellular component (CC) terms and pathways. The analysis tool was the Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.niaid.nih.gov) (19), which is an integrated biological knowledgebase used for the systematic and integrative analysis of large gene protein lists. The P-value <0.05 and enrichment count ≥2 were considered as thresholds.

PPI network construction

The Search Tool for the Retrieval of Interacting Genes (STRING) (http://string-db.org/) database (20) is a precomputed global resource used for evaluating PPI information. In the present study, the STRING online tool was applied to predict the PPI pairs of DEGs with a combined score of >0.4. The PPI network was constructed using cytoscape (21). Additionally, 3 methods including degree centrality, betweenness centrality and subgraph centrality were used to analyze the hub gene in the PPI network using the CytoNCA cytoscape plugin (http://apps.cytoscape.org/apps/cytonca) (22).

TF analysis

In order to predict the role of TFs in hypertension, we selected the TFs from the DEG corresponding proteins, and predicted the target associations between the TFs and the DEGs based on the TRANSFAC database in the iRegulon cytoscape plugin (http://iregulon.aertslab.org) (23), as previously described. FDR on motif similarity <0.05 was regarded as the threshold.

Analysis of DEGs in the HF and HM groups

In the present study, we screened the common DEGs between the HF and HM groups in order to analyze the similarity of hypertension in females and males. Subsequently, these selected DEGs were subjected to GO functional enrichment analysis using DAVID. Furthermore, the enriched GO terms were subjected to correlation analysis using the enrichmentmap cytoscape plugin (http://baderlab.org/Software/EnrichmentMap/) (24) (P<0.05).

Results

Identification of DEGs

In total, 201 upregulated and 210 downregulated DEGs were identified between the HF and NF groups. Moreover, 204 upregulated and 214 downregulated DEGs were identified between the HM and NM groups. The results are presented in the heatmaps in Fig. 1A and B.
Figure 1

Heatmap plot of differentially expressed genes accross all samples. (A) Hypertensive female (HF) vs. normotensive female (NF); (B) hypertensive male (HM) vs. normotensive male (NM). Red stands for high expression value and green stands for low expression value. The changes of color from green to red stands for the changes of expression value from low to high.

GO and pathway enrichment analyses of DEGs

The upregulated DEGs in the HF group were mainly enriched in GO terms related to ion transport and oxidation reduction, and in the pathway of histidine metabolism. The downregulated DEGs were mainly enriched in the GO terms related to steroid metabolic process and microsome, and in the pathway of arachidonic acid metabolism (Table I).
Table I

Functional enrichment analysis for the DEGs of the HF group.

TermCountP-value
UpBPGO:0006811-ion transport195.68E-05
GO:0019751-polyol metabolic process46.56E-03
GO:0055114-oxidation reduction131.66E-02
CCGO:0005576-extracellular region324.98E-04
GO:0042383-sarcolemma41.17E-02
GO:0005886-plasma membrane411.75E-02
MFGO:0022836-gated channel activity101.00E-03
GO:0005216-ion channel activity104.35E-03
GO:0022838-substrate specific channel activity105.32E-03
KEGGmmu00340:Histidine metabolism31.96E-02
mmu03320:PPAR signaling pathway43.10E-02
DownBPGO:0008202-steroid metabolic process97.92E-05
GO:0055114-oxidation reduction172.25E-04
GO:0010565-regulation of cellular ketone metabolic process49.96E-04
CCGO:0005792-microsome92.16E-04
GO:0042598-vesicular fraction92.71E-04
GO:0005783-endoplasmic reticulum196.14E-04
MFGO:0030414-peptidase inhibitor activity112.89E-06
GO:0004866-endopeptidase inhibitor activity101.06E-05
GO:0004857-enzyme inhibitor activity114.83E-05
KEGGmmu00590:Arachidonic acid metabolism53.56E-03
mmu00511:Other glycan degradation36.44E-03
mmu00830:Retinol metabolism41.49E-02
mmu04610:Complement and coagulation cascades41.94E-02

DEGs, differentially expressed genes; HF, hypertensive female; up, upregulated DGEs; down, downregulated DEGs; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes.

In the HM group, the upregulated DEGs were mainly enriched in GO terms related to co-factor metabolic process and oxidation reduction, and in the pathway of PPAR signaling. The downregulated DEGs were mainly enriched in GO terms related to hormone metabolic process and endoplasmic reticulum (Table II).
Table II

Functional enrichment analysis for the DEGs of the HM group.

TermCountP-value
UpBPGO:0051186-cofactor metabolic process81.04E-03
GO:0055114-oxidation reduction152.04E-03
GO:0019748-secondary metabolic process53.02E-03
CCGO:0005576-extracellular region374.68E-06
GO:0005777-peroxisome52.03E-02
GO:0042579-microbody52.03E-02
MFGO:0019842-vitamin binding101.64E-06
GO:0016290-palmitoyl-CoA hydrolase activity38.12E-03
GO:0030170-pyridoxal phosphate binding41.33E-02
KEGGmmu03320:PPAR signaling pathway56.25E-03
mmu00590:Arachidonic acid metabolism57.43E-03
DownBPGO:0042445-hormone metabolic process71.63E-04
GO:0010817-regulation of hormone levels71.07E-03
GO:0042398-cellular amino acid derivative biosynthetic process49.31E-03
CCGO:0005783-endoplasmic reticulum151.29E-02
MFGO:0004866-endopeptidase inhibitor activity73.52E-03
GO:0030414-peptidase inhibitor activity75.43E-03
GO:0004867-serine-type endopeptidase inhibitor activity52.09E-02

DEGs, differentially expressed genes; HM, hypertensive male; up, upregulated DGEs; down, downregulated DEGs; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes.

The constructed PPI network based on the DEGs between the HF and NF groups is shown in Fig. 2A. The PPI network consisted of 193 nodes and 301 interaction pairs. The top 10 hub genes were selected based on the analysis of degree centrality, betweenness centrality and subgraph centrality. Among the 10 genes, cytochrome P450, family 2, subfamily E, polypeptide 1 (Cyp2e1) had the highest degree in all the 3 analysis methods (Table III).
Figure 2

The constructed protein-protein interaction (PPI) network for differentially expressed genes (DEGs). Pink stands for upregulated DEGs and green stands for downregulated DEGs. (A) Hypertensive female (HF) vs. normotensive female (NF); (B) hypertensive male (HM) vs. normotensive male (NM).

Table III

The top 10 network nodes in the HF group based on the analysis of degree centrality, betweenness centrality and subgraph centrality.

GeneDegreeBetweennessSubgragh
Cyp2e118Cyp2e17915.4395Cyp2e1295.83835
Cyp4a12a16Aldh1a14667.3003Cyp4a12a279.15607
Cyp2b1011Pla2g54572.402Cyp2b10179.15228
Pla2g59Srebf14370.598Slc22a30100.235176
Srebf19Dkk14108.5645Pla2g599.77931
Serpina1d9Cyp4a12a3427.9216Slco1a199.73588
Cyp7b19Pld13171.1284Cyp4f1881.0327
Slc22a309Serpina1d3132.0713Cyp4f1481.03269
Anxa18Prok13062.5642Aldh1a173.60265
Gm2668Plcl22823.1924Aldh1a769.66662

HF, hypertensive female.

The PPI network constructed by the DEGs between HM and NM included 182 nodes and 248 PPI interaction pairs (Fig. 2B). The top 10 hub genes respectively analyzed by 3 methods are shown in Table IV, namle UDP glucuronosyltransferase 2 family, polypeptide B37 (Ugt2b37), formimidoyltransferase cyclodeaminase (Ftcd) and cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14).
Table IV

The top 10 network nodes in the HM group based on the analysis of degree centrality, betweenness centrality and subgraph centrality.

GeneDegreeBetweennessSubgragh
Ugt2b3711Ftcd5603.764Cyp4a1457.048008
Cyp4a1010Lep4363.4756Cyp4a1055.98465
Cyp4a1410Ugt2b374147.9277Ppbp52.882313
Lep10Serpina1d4005.5542Ugt2b3750.838398
Ppbp9Cyp4a143500.8042Aldh1a734.876118
Tgfb28Fcgr2b2844.4468Aldh1a134.272568
Ftcd8Pld12784.8557Aplnr28.300505
Aldh1a77Plcl22771.22Grm728.300499
Aldh1a17Il10rb2728.78Adra2b28.300493
A2m7Synj22569.02Oxgr128.300491

HM, hypertensive male.

Based on the TRANSFAC database in iRegulon, the TFs in the HF and HM samples were predicted and the transcriptional regulatory networks were constructed (Fig. 3A and B). In the HF group, the TFs were sterol regulatory element binding transcription factor 1 (Srebf1) and estrogen receptor 1 (Esr1). In the HM group, the TFs were retinoid X receptor gamma (Rxrg) and peroxisome proliferator-activated receptor gamma (Pparg).
Figure 3

The constructed transcriptional regulatory network. Octagon stands for transcription factor; circle stands for differentially expressed genes (DEGs) in hypertensive female (HF); square stands for DEGs in hypertensive male (HM). Pink stands for upregulated DEGs and green stands for downregulated DEGs. (A) HF group; (B) HM group.

There were 118 intersection genes among the upregulated DEGs in the HF and HM samples; they were mainly distributed in chromosomes 4 and 7. Among the downregulated DEGs, 112 were intersection genes and they were mainly distributed in chromosomes 11 and 14. Moreover, these intersection genes were mainly enriched in BP terms related to catecholamine biosynthetic process, CC terms related to extracellular region and MF terms related to endopeptidase inhibitor activity (Table V). For instance, lysyl oxidase-like 2 (Loxl2) was enriched in the CC term related to extracellular region. The interaction network for these terms are shown in Fig. 4.
Table V

The significant functions enriched by the intersection genes.

TermCountP-value
BPGO:0042423-catecholamine biosynthetic process30.004975549
GO:0006638-neutral lipid metabolic process40.007615151
GO:0042445-hormone metabolic process50.008732351
CCGO:0005576-extracellular region314.56E-04
GO:0000267-cell fraction120.02798221
GO:0005626-insoluble fraction110.030455631
MFGO:0004866-endopeptidase inhibitor activity91.17E-04
GO:0030414-peptidase inhibitor activity92.16E-04
GO:0004867-serine-type endopeptidase inhibitor activity76.59E-04

BP, biological process; CC, cellular component; MF, molecular function.

Figure 4

The interaction network for the terms enriched by intersection genes. Node stands for Gene Ontology (GO) term, the more the number of gene that was enriched in term, the bigger the node. Edge stands for the interaction between terms, the more the number of intersection genes, the thicker the edge.

Discussion

In the present study, 411 DEGs were identified between the HF and NF samples, and 418 DEGs were identified between the HM and NM samples. The upregulated DEGs, Cyp4b1 and Cyp4a31, were mainly enriched in BP terms related to oxidation reduction in both the HF and HM samples. In addition, Esr1, Pparg and Rxrg were the key TFs involved in the transcriptional regulatory networks. Following the analysis of DEGs in the HF and HM samples, many intersection DEGs were identified between the 2 groups, such as Loxl2. These genes and TFs may play important roles in the progression of hypertension. Previous studies have indicated that reactive oxygen species play an important pathophysiological role in the development of cardiovascular diseases, including hypertension (25,26). In human hypertension, biomarkers of systemic oxidative stress have been found to be elevated (27). In the present study, BP terms related to oxidation reduction were significant terms enriched by the DEGs in both the HF and HM samples. For instance, several cytochrome P450 (CYP)-associated genes, including Cyp4b1 and Cyp4a31 were enriched in this BP term. CYPs are important enzymes involved in the oxidative and reductive metabolism of numerous endogenous compounds in mammals (28). In the study by Chiu et al (2), Cyp4b1 was validated to be differentially expressed between hypertensive and normotensive mice by qPCR. CYP4A proteins have been found in vascular tissues (29) and have been suggested to be linked to hypertension in numerous experimental models (30). Sacerdoti et al (31) demonstrated that the inhibition or depletion of CYP4A activity can lower blood pressure in the spontaneously hypertensive rat. Of note, Cyp4a31 was found enriched in the PPAR signaling pathway in HF and HM samples. The PPARs are members of the nuclear receptor family of ligand-activated TFs, which play an important role in the regulation of cardiovascular circadian rhythms (32). Therefore, the upregulation of Cyp4b1 and Cyp4a31 in our study was in accordance with previous research. The 2 DEGs may be critical biomarkers associated with human hypertension. In addition, Esr1 was a key TF in the transcriptional regulatory networks of the HF sample group. Esr1 is a member of the family of ESRs, belonging to superfamily of nuclear receptor TFs. This receptor is expressed in a wide range of tissues and cells, including vascular smooth muscle and vascular endothelial cells (33). Estrogen can increase vasodilatation and inhibit the development of atherosclerosis (33). Specifically, the incidence of cardiovascular disease, including hypertension differs between males and females (34). Accumulating evidence suggests that estrogen deficiency plays a major role in the pathogenesis of cardiovascular diseases in post-menopausal women (35). In our study, the TF, Esr1, was also identified in female hypertensive mice, which indicated that Esr1 may play an important role in the progression of hypertension in females. Furthermore, the TFs, Pparg and Rxrg, were involved in the transcriptional regulatory networks in the HM samples. Pparg is a member of PPARs which, as mentioned above, play an important role in the regulation of cardiovascular circadian rhythms. Pparg has been implicated in atherosclerosis (36), coronary heart disease (37) and hypertension (38). RXRs are members of the NR2B family of nuclear receptors and are major heterodimerization partners of PPARs (39). RXRs are involved in mediating the anti-proliferative effects of retinoic acid, which can comprise a collection of molecules with retinoids to maintain homeostasis in adults (40). A growing number of studies have reported the role of RXRs and PPARs in controlling cellular metabolism in tissues, including the myocardium (40,41). Nohara et al (39) suggested that a variant of Rxrg contributes to human genetic dyslipidemia. Taken together, the TFs, Pparg and Rxrg, may have utility in the diagnose and treatment of hypertension. Following the analysis of DEGs in the HF and HM samples, we found that there were many intersection DEGs between the 2 groups, such as Loxl2. This DEG was found enriched in the BP terms related to oxidation reduction and CC terms related to extracellular region. Loxl2 encodes a member of the lysyl oxidase gene family, which are extracellular copper-dependent amine oxidases initiating the formation of crosslinks in collagen and elastin (42). The collagen and elastin are important components of the extracellular matrix (43). It has been found that the activity of lysyl oxidase is essential to maintain the features of connective tissues, including cardiovascular systems (44). The deregulation of lysyl oxidase is associated with aneurysms, aortic rupture and different stages of the atherosclerotic process (45,46). Presently, there are few studies on the association between lysyl oxidase and hypertension. Thus, we speculated that Loxl2 may be a potential biomarker for the progression of hypertension. In conclusion, our study provides a comprehensive bioinformatics analysis of biomarkers in hypertension, which may provide new insight into the mechanisms responsible for this disease. The DEGs, Cyp4b1, Cyp4a31 and Loxl2, and the TFs, Esr1, Pparg and Rxrg, may be associated with the progression of hypertension, and may serve as potential therapeutic targets in this disease. However, there was a limitation to this study. The present study was implemented by means of bioinformatics; therefore, the screened genes and TFs have not been validated by actual experiments. As a result, further experimental studies with a larger sample size are warranted to confirm the results of our study.
  43 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Molecular mechanisms of human hypertension.

Authors:  R P Lifton; A G Gharavi; D S Geller
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  The Benjamini-Hochberg method in the case of discrete test statistics.

Authors:  José A Ferreira
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

4.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture.

Authors:  E Barrett-Connor
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 6.  Advances in genetic hypertension.

Authors:  Scott S Williams
Journal:  Curr Opin Pediatr       Date:  2007-04       Impact factor: 2.856

Review 7.  Protective effects of estrogen on the cardiovascular system.

Authors:  Michael E Mendelsohn
Journal:  Am J Cardiol       Date:  2002-06-20       Impact factor: 2.778

8.  Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries.

Authors:  Jackleen S Marji; Mong-Heng Wang; Michal Laniado-Schwartzman
Journal:  Am J Physiol Renal Physiol       Date:  2002-07

9.  Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension.

Authors:  Harpreet Singh; Jennifer Cheng; Huan Deng; Rowena Kemp; Tsuneo Ishizuka; Alberto Nasjletti; Michal Laniado Schwartzman
Journal:  Hypertension       Date:  2007-06-04       Impact factor: 10.190

10.  Identification of genes with altered expression in male and female Schlager hypertensive mice.

Authors:  Christine L Chiu; Kristy L Jackson; Nerissa L Hearn; Nicole Steiner; Geoffrey A Head; Joanne M Lind
Journal:  BMC Med Genet       Date:  2014-08-30       Impact factor: 2.103

View more
  4 in total

1.  Lysyl oxidase-like 2 depletion is protective in age-associated vascular stiffening.

Authors:  Jochen Steppan; Huilei Wang; Yehudit Bergman; Marcel J Rauer; Siqi Tan; Sandeep Jandu; Kavitha Nandakumar; Sebastian Barreto-Ortiz; Robert N Cole; Tatiana N Boronina; Wanqu Zhu; Marc K Halushka; Steven S An; Dan E Berkowitz; Lakshmi Santhanam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-19       Impact factor: 4.733

Review 2.  Mechanisms Responsible for Genetic Hypertension in Schlager BPH/2 Mice.

Authors:  Kristy L Jackson; Geoffrey A Head; Cindy Gueguen; Emily R Stevenson; Kyungjoon Lim; Francine Z Marques
Journal:  Front Physiol       Date:  2019-10-18       Impact factor: 4.566

3.  Lysyl oxidase family gene polymorphisms and risk of aneurysmal subarachnoid hemorrhage: a case-control study.

Authors:  Chun Luo; Bingyang Li; Chao Liu; Rui Dong; Chongyu Hu; Junyu Liu; Liming Hu; Xin Liao; Jilin Zhou; Lu Xu; Songlin Liu; Dun Yuan; Weixi Jiang; Junxia Yan; Yifeng Li
Journal:  Ann Transl Med       Date:  2022-09

4.  Identification of Target Genes in Hypertension and Left Ventricular Remodeling.

Authors:  Bo Pang; Cong Hu; Guodong Wu; Yanli Zhang; Guangzhu Lin
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.